AA
CKPT

ALPS Advisors’s Checkpoint Therapeutics CKPT Stock Holding History

ALPS Advisors’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,609
Closed -$152K – 1043
2022
Q1 		$152K Sell
8,609
-1,085
-11% -$23.3K ﹤0.01% 816
2021
Q4 		$301K Buy
+9,694
New +$321K ﹤0.01% 830

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ALPS Advisors's CKPT Position: Q2 2022 in Review

ALPS Advisors sold out of Checkpoint Therapeutics (CKPT) in Q2 2022, closing a stake of 8,609 shares — an estimated $152K sold.

ALPS Advisors first reported a position in CKPT in Q4 2021 and held it in 2 quarters. The position peaked at $301K in Q4 2021. 62 funds tracked by Wall St. Rank hold CKPT as of Q2 2022.

  • ALPS Advisors reported no remaining Checkpoint Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 8,609 Checkpoint Therapeutics shares in Q2 2022, an estimated $152K.
  • ALPS Advisors first reported a position in Checkpoint Therapeutics in Q4 2021 and held it in 2 quarters.
  • ALPS Advisors's Checkpoint Therapeutics position peaked at $301K in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.